Regenerative Medicine Advanced Manufacturing is a new goal for SAS’s data analytics. | So Good News


Research Triangle Park – Winston-Salem-based nonprofit Regenerative Medicine Development Organization (ReMDO) and Cary-based analytics firm SAS are joining forces to advance advanced manufacturing for regenerative medicine applications.

SAS provides companies with state-of-the-art biomanufacturing equipment; SAS will contribute its expertise to ReMDO’s RegeneratOR Test Bed, providing industry expertise. skills, Training programs to support the development of innovative prototyping and commercial products.

SAS develops drug therapies; It also brings to the alliance decades of experience in life sciences, providing companies with technologies to improve manufacturing and commercialization of medical treatments.

RegeneratOR Test Bed Core Tech Katie Benson oversees equipment.
RegeneratOR Test Bed Core Tech Katie Benson oversees equipment.
ReMDO photo

Cooperation is diversity; It is intended to help regenerative medicine companies improve product yields while reducing contamination and costs.

“Regenerative medicine is called the next evolution of medical care, and SAS is excited to participate in this innovative and important project,” said Udo Sglavo, Vice President of Advanced Analytics R&D at SAS. “SAS’s IoT division and Advanced Analytics Center of Excellence will apply our related industry expertise, proven software solutions and data analytics techniques to the Regenerator Test Bed to help improve production potential and achieve better results.”

The Test Bed is sponsored by ReMDO, a non-profit foundation dedicated to advancing regenerative medicine nationwide, and the World’s Largest Foundation for Regenerative Medicine (WFIRM).

Joshua Hunsberger, ReMDO’s chief technology officer, said SAS’s technology will be a game changer for startup companies.

“Any company in our Regenerative Medicine Hub will have access to smart manufacturing capabilities,” he said, referring to the Triad region’s regenerative medicine ecosystem. “These services will help companies predict and optimize the best manufacturing processes, saving time and money.”

Anthony Atala, MD, director of WFIRM, said, “Through its partnership with SAS, Test Bed has a lot to offer in helping these companies succeed, while at the same time we can improve resurgence in the medical field nationwide.

The Test Bed is one of three areas of focus through ReMDO’s Regenerator initiative, advancing biomanufacturing scale and automation to make technologies more affordable and accelerate translation into clinical practice.

Two other areas are the Innovation Accelerator and Colleges, which support innovation from research to innovation for resurgent drug companies of all sizes. biomanufacturing staff to university programs and technical schools; a Workforce Development program that connects engineers and research leaders; Train biomanufacturing technicians and researchers.

Regenerator includes more than 30 companies and organizations.

“It’s exciting to see world-renowned North Carolina professionals working together with industry to help grow companies and attract new opportunities within this growing regenerative medicine center,” said Nancy Johnston, executive director of the North Carolina Biotechnology Center’s Piedmont Triad Office. The Center collaborates with SAS and WFIRM and its associated strains, and Atala is a member of the NCBiotech Board of Directors.

ReMDO WFIRM and their various resources are biomedical sciences; information Technology, digital media; research for clinical services and advanced materials; It is based in Winston-Salem’s Innovation Quarter, a downtown district focused on business and education.

Regenerative Medicine uses human or animal organs; tissues, cells, to extend genes and disease-damaged, injury- or aging-related metabolic processes; to repair A new and rapidly growing field of medicine is medicine aimed at replacement or regeneration.

The global market for regenerative medicine reached $9.8 billion in 2021 and is expected to grow to $37.1 billion by 2030, according to a recent analysis by Surrey-based Canadian market research and consulting firm Emergen Research. British Columbia;

(c) NC Department of Biotechnology


Source link